Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fensolvi in Children with Central Precocious Puberty
NCT02452931Phase 3Completed
- Sponsor
- Tolmar
- Start
- Aug 2015
- Primary completion
- Sep 2018
- Modality
- Peptides, Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of TOL-2506 in central precocious puberty (CPP), sponsored by Tolmar. Primary endpoint: Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months. Started Aug 2015; status: completed.
02
Drugs
TOL-2506
03
Conditions
central precocious puberty (CPP)
Beyond the preview
Go deeper on NCT02452931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452931.